Biotech Axoltis pharma Launches Funding Drive for Promising ALS treatment
Lyon, France โค- October 8, 2024 – French biotechโ firm Axoltis Pharma today โฃannounced a public fundraising โขcampaign to accelerate the progress of NX210C, a novel treatment currently in late-stage clinical trials forโ Amyotrophicโค Lateral Sclerosis (ALS), also knownโข as Charcot’s disease. The move offers the โคpublic an possibility to invest in a โคpotential breakthrough for a โdisease with limited therapeutic โoptions.
ALS is a progressive neurodegenerative disease affecting motor neurons, โleading to muscle weakness, paralysis, and ultimately,โ death. Currently,โ treatments focus on managing symptoms and slowing disease progression, offering only modest benefits. axoltis Pharma believes NX210C representsโข “a โnew therapeutic โoutlook and hope for โpatients,” aiming to provide a more effectiveโ response where current approachesโ fall short, โคaccording โto Chairman of the Biotech Managementโฃ Board, Yann Godfrin.
clinical trials, led by Dr. รmilien Bernard of the Reference Center Rareโข Diseases of Civil Hospices in Lyon, areโ nearing completion of phase 2, involving 80 patients. Preliminary data from a phaseโข 1B study in โ2023 indicated a “good profile of tolerance” for NX210C, according to Axoltis Pharma.Phase โ2 results evaluating the drug’s effectiveness โคare expectedโค by April 2026, followed by two further phases toโฃ confirm therapeutic benefits and conduct a large-scaleโฃ assessment.
the fundraising campaign, hosted on the Capital Cell platform, is openโฃ until the end of october โand โขseeks โขto accelerate theโ drug’s development. โ”With NX210C, we have โฃtheโ ambition to provide a therapeutic response where there are only very modestly effective approaches โขtoday,” โฃGodfrin stated. “Opening our capital to the โgeneral public is allowing everyone to take โคpartโฃ in the clinical development โฃof an innovative and very promising drug for the treatment of neurodegenerative diseases such as ALS.”